90
Participants
Start Date
February 22, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2027
Disitamab Vedotin Injection
Phase II and III study ：2.5mg/kg, intravenous infusion，D1, every 2 weeks
Cadonilimab Injection
Phase II and III study ：6.0mg/kg, intravenous infusion，D1, every 2 weeks.
Paclitaxel Injection
Phase II and III study ：Calculate dosage based on body surface are,160mg/m2,intravenous infusion，D1,D8 every 3 weeks
RECRUITING
Beijing Cancer Hospital, Beijing
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital, Harbin
NOT_YET_RECRUITING
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
RECRUITING
Xuzhou Central Hospital, Xuzhou
RECRUITING
Shandong Cancer Hospital, Jinan
NOT_YET_RECRUITING
The Affiliated Hospital of Qingdao University, Qingdao
NOT_YET_RECRUITING
The First Affiliated Hospital of Xiamen University, Xiamen
RECRUITING
Hunan Cancer Hospital, Changsha
NOT_YET_RECRUITING
Hubei Cancer Hospital, Wuhan
NOT_YET_RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
NOT_YET_RECRUITING
West China Hospital of Sichuan University, Chengdu
RECRUITING
Yunnan Cancer Hospital, Kunming
RemeGen Co., Ltd.
INDUSTRY